Alpha Teknova, Inc. (TKNO) Stock Analysis

Company Overview

Alpha Teknova, Inc. (TKNO) is capitalised at $371.52M on the latest close. The company sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry. Headcount on file is 158.

Over the past 52 weeks the price has ranged from $1.91 to $7.84. TKNO last closed at $6.92 on September 4, 2026. That is −$0.32 (−4.42%) against the previous close. The latest close sits 262.3% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $40.52M. That is +7.35% against the prior fiscal year, when revenue was $37.75M. The same year closed with a net loss of $17.26M. Profit margin runs at −38.37%. That is 35.2 percentage points below the Drug Manufacturers - Specialty & Generic median of −3.14%. Earnings per share on a trailing basis come to −0.31.

Across the 4 fiscal years on file, revenue moves from $41.42M in 2022 to $40.52M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 8.5. On price-to-sales that is 3.7 times the Drug Manufacturers - Specialty & Generic median of 2.3. 103 Drug Manufacturers - Specialty & Generic companies report these metrics, and the medians quoted come from that group.

The reported beta is 0.73. Daily returns over the trailing 5 years annualize to a volatility of 93.3%. The trailing one-year price return is +63.21%. Measured over 5 years, that is −18.27% a year compounded.

Growth & Income

The record shows no dividend for TKNO.

2026 is still running; the price is +82.11% year to date. The strongest complete calendar year on file is 2024 at +123.86%; the weakest is 2022 at −72.46%. Of the 4 complete calendar years on file, 1 finished higher.